Life sciences November 19, 2018

ADC Bio raises series D for continued development of cancer killing ADC tech

We were delighted to act for Downing LLP on its investment of VCT and EIS funds into ADC Biotechnology Limited, following on from Downing’s investment earlier in the year in what was ADC Bio’s series C (reported by HLaw here).  This latest funding round for ADC Bio round raised £2.5 million in new equity finance.

Deal/project: Series D funding round

Date closed: October 2018

Space: Life sciences

Other lawyers and advisors: DWF (Frank Shepherd & team) acted for the company; Marriott Harrison advised Maven Capital; BioScience Managers also advised Downing LLP


£2.5 million

Team advising
Share on Social Media